APP and tauopathy: In contrast, inhibition of C3aR reduced glial activity and rescued neuronal defects in a tauopathy model (PS19 mice) [49], and C3aR antagonist-treated APP-transgenic mice had a reduced plaque burden compared to control AD mice [50].